Phase I results of a novel FGFR inhibitor

Bookmark and Share
Published: 9 Oct 2016
Views: 1260
Rating:
Save
Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland

Dr Joerger speaks with ecancertv at ESMO 2016 about a novel FGFR inhibitor for solid tumours, BAY 1163877, which unusually assesses patient suitability based on mRNA expression.

He describes results of the dose escalation study, which tested five doses ranging from 50–800 mg BID (twice daily), and anticipates further based on expansion cohorts already tested.

 Read the news coverage here.